Business Context and Reporting Period
Company: Altimmune, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 22, 2018
Event: Entry into Material Definitive Agreements involving the exchange of existing warrants and preferred stock for new equity, convertible notes, and cash.
Key Financial Metrics and Transaction Details
This filing details a specific capital restructuring transaction rather than periodic financial performance. Key metrics disclosed include:
- Cash Consideration Paid: $1,100,000 in aggregate cash to investors.
- Common Stock Issued: 2,560,693 shares of Common Stock ("Exchange Common Shares").
- Convertible Notes Issued: $1,500,000 in aggregate principal value ("Exchange Notes").
- Conversion Potential: Exchange Notes are convertible into up to 2,205,883 shares of Common Stock upon default.
- Outstanding Common Stock: 34,746,022 shares as of June 22, 2018.
- Remaining Series B Preferred Stock: 557,475 shares outstanding post-transaction.
- Remaining Warrants: Warrants to purchase 751,674 shares of Common Stock outstanding post-transaction.
Note: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or total debt levels outside of the specific transaction details.
Material Changes Versus Prior Period
The filing reports a material change in the company's capital structure through the "Exchange" transaction:
- Termination of Obligations: All obligations under the August 16, 2017 Securities Purchase Agreement and the Certificate of Designations for Series B Convertible Preferred Stock held by the participating investors are terminated.
- Debt and Equity Shift: Existing warrants held by investors were exchanged for a combination of cash, new common stock, and new convertible notes.
- Preferred Stock Repayment: Investors received cash in lieu of shares for the final two installment payments of Series B Convertible Preferred Stock.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Conditions:
- Closing Conditions: The transaction is subject to the listing of Exchange Common Shares and Exchange Conversion Shares on the NASDAQ Global Market and other customary closing conditions.
- Investor Rights: Investors granted voting rights to support the Board's director nominees and proposals at the 2018 annual meeting. They also received preemptive rights for two years and "most favored nation" pricing protections for future exchanges.
- Covenants: The Exchange Notes include customary covenants restricting liens and the incurrence of additional indebtedness.
Risks and Contingencies:
- Default Risk: The Exchange Notes are convertible into equity specifically upon the default by the Company.
- Regulatory Exemption: The securities were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, exempting them from registration requirements.
Important Facts for Investor Verification
- Verify the successful listing of the new shares on the NASDAQ Global Market to confirm the transaction closing.
- Review the full text of the Exchange Agreements (Exhibits 10.1 and 10.2) for specific default triggers and conversion price adjustments.
- Monitor the impact of the $1,100,000 cash outflow on the company's immediate liquidity position.
- Confirm the voting alignment of the new investors at the upcoming 2018 annual meeting of stockholders.
- Assess the dilution impact of the 2,560,693 new shares and the potential 2,205,883 conversion shares against the 34.7 million shares outstanding.